Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-FLAVOR: Tenecteplase vs alteplase for large vessel occlusion recanalization
jRCTs051210055Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial in ischemic stroke comparing Tenecteplase arm with Alteplase arm (2 arms). Primary endpoints: Symptomatic intracranial hemorrhage within 24–36 hours (safety confirmation phase), Substantial angiographic recanalization (mTICI 2b/2c/3) or absence of retrievable thrombus at initial angiogram and 2 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on jRCTs051210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210055.